ArticleBiological research2025
Human placenta-derived endothelial progenitor cells: an animal-free culture system for efficient expansion.
Article in Biological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal Bioactive Approaches in Smart Dressings for Diabetic Foot Ulcers.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEndothelial progenitor cells (EPCs) play a critical role in vasculogenesis and vascular repair, but their clinical application is hindered by challenges such as cell purity, quantity, and reliance on fetal bovine serum (FBS). This study developed an animal-free system for isolating, induction, and expanding EPCs from the human placenta, evaluating their potential for wound repair.
methodsMononuclear cells (MNCs) were isolated from full-term placenta and induced into EPCs using an animal-free medium supplemented with bFGF, IGF, and VEGF. EPCs were characterized by flow cytometry for markers CD133, CD34, and VEGFR2, while CD31 and CD45 served as negative markers. Functional assays, including Ac-LDL uptake, migration, and tube formation, confirmed EPC properties. The wound-repair potential was assessed in a mouse model.
resultsThe induced EPCs exhibited high purity (> 95%) and expressed CD133, CD34, and VEGFR2 while being negative for CD31 and CD45. The system yielded 1 × 10⁸ EPCs from 10 g of placental tissue, demonstrating high proliferative capacity. Functional assays confirmed robust tube formation, migration, and Ac-LDL uptake in vitro. In vivo, EPCs significantly enhanced wound repair.
conclusionsIn conclusion, human placenta-derived EPCs cultured in an animal-free system displayed high purity, self-renewal capacity, and functional efficacy, making them a promising cell source for therapeutic applications, particularly in wound repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.